Compare
Catheter Precision, Inc. vs Co-Diagnostics, Inc. vs RenovoRx, Inc. vs PetVivo Holdings, Inc.
| Latest fiscal year | Catheter Precision, Inc. VTAK | Co-Diagnostics, Inc. CODX | RenovoRx, Inc. RNXT | PetVivo Holdings, Inc. PETV |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-03-31 |
| Revenue | $819.0K | $622.5K | $1.12M | $1.14M |
| Revenue growth (YoY) | +95.0% | -84.1% | n/m | +0.8% |
| Gross margin | 92.3% | 64.3% | 70.9% | 66.1% |
| Operating margin | n/m | n/m | n/m | -793.9% |
| Net margin | n/m | n/m | -994.5% | -917.4% |
| Net income | -$17.18M | -$46.90M | -$11.17M | -$10.47M |
| EPS (Diluted) | n/a | -$35.25 | -$0.32 | -$0.38 |
| Operating cash flow | -$8.30M | -$29.14M | -$10.97M | -$6.11M |
| Free cash flow | -$8.31M | -$29.84M | -$10.97M | -$6.12M |
| Cash & equivalents | $88.0K | $11.88M | $7.02M | n/a |
| Total assets | $15.86M | $24.74M | $8.10M | $3.58M |
| Total liabilities | $9.21M | $4.11M | $2.67M | $1.38M |
| Shareholders' equity | $7.05M | $20.63M | $5.42M | $2.20M |
| Return on year-end equity | -243.6% | -227.3% | -206.0% | -476.2% |
| Shares outstanding | 1.74M | 2.10M | 36.61M | 35.85M |
Revenue, most recent five fiscal years
| Fiscal year | Catheter Precision, Inc. | Co-Diagnostics, Inc. | RenovoRx, Inc. | PetVivo Holdings, Inc. |
|---|---|---|---|---|
| Latest | $819.0K Ended 2025-12-31 | $622.5K Ended 2025-12-31 | $1.12M Ended 2025-12-31 | $1.14M Ended 2026-03-31 |
| 1 year earlier | $420.0K Ended 2024-12-31 | $3.92M Ended 2024-12-31 | $43.0K Ended 2024-12-31 | $1.13M Ended 2025-03-31 |
| 2 years earlier | $442.0K Ended 2023-12-31 | $6.81M Ended 2023-12-31 | n/a | $968.7K Ended 2024-03-31 |
| 3 years earlier | $14.0K Ended 2022-12-31 | $34.22M Ended 2022-12-31 | n/a | $917.2K Ended 2023-03-31 |
| 4 years earlier | $22.0K Ended 2021-12-31 | $97.89M Ended 2021-12-31 | n/a | $115.6K Ended 2022-03-31 |